Header

UZH-Logo

Maintenance Infos

Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - An open pilot study


Biedermann, Luc; Mwinyi, Jessica; Scharl, Michael; Frei, Pascal; Zeitz, Jonas; Kullak-Ublick, Gerd A; Vavricka, Stephan R; Fried, Michael; Weber, Achim; Humpf, Hans-Ulrich; Peschke, Simone; Jetter, Alexander; Krammer, Gerhard; Rogler, Gerhard (2013). Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - An open pilot study. Journal of Crohn's & colitis, 7(4):271-279.

Abstract

BACKGROUND AND AIMS: A significant fraction of patients with ulcerative colitis (UC) is not sufficiently controlled with conventional therapy or suffers from therapy related side effects. Anthocyanins, highly abundant in bilberries (Vaccinium myrtillus), were shown to have antioxidative and anti-inflammatory effects. We aimed to explore the therapeutic potential of bilberries in active UC. METHODS: In an open pilot trial with a total follow-up of 9weeks the effect of a daily standardized anthocyanin-rich bilberry preparation was tested in 13 patients with mild to moderate UC. Clinical, biochemical, endoscopic and histologic parameters were assessed. RESULTS: At the end of the 6week treatment interval 63.4% of patients achieved remission, the primary endpoint, while 90.9% of patients showed a response. In all patients a decrease in total Mayo score was detected (mean: 6.5 and 3.6 at screening and week 7, respectively; p<0.001). Fecal calprotectin levels significantly decreased during the treatment phase (baseline: mean 778μg/g, range 192-1790μg/g; end of treatment: mean 305μg/g, range <30-1586μg/g; p=0.049), including 4 patients achieving undetectable levels at end of treatment. A decrease in endoscopic Mayo score and histologic Riley index confirmed the beneficial effect. However, an increase of calprotectin levels and disease activity was observed after cessation of bilberry intake. No serious adverse events were observed. CONCLUSIONS: This is the first report on the promising therapeutic potential of a standardized anthocyanin-rich bilberry preparation in UC in humans. These results clearly indicate a therapeutic potential of bilberries in UC. Further studies on mechanisms and randomized clinical trials are warranted.

Abstract

BACKGROUND AND AIMS: A significant fraction of patients with ulcerative colitis (UC) is not sufficiently controlled with conventional therapy or suffers from therapy related side effects. Anthocyanins, highly abundant in bilberries (Vaccinium myrtillus), were shown to have antioxidative and anti-inflammatory effects. We aimed to explore the therapeutic potential of bilberries in active UC. METHODS: In an open pilot trial with a total follow-up of 9weeks the effect of a daily standardized anthocyanin-rich bilberry preparation was tested in 13 patients with mild to moderate UC. Clinical, biochemical, endoscopic and histologic parameters were assessed. RESULTS: At the end of the 6week treatment interval 63.4% of patients achieved remission, the primary endpoint, while 90.9% of patients showed a response. In all patients a decrease in total Mayo score was detected (mean: 6.5 and 3.6 at screening and week 7, respectively; p<0.001). Fecal calprotectin levels significantly decreased during the treatment phase (baseline: mean 778μg/g, range 192-1790μg/g; end of treatment: mean 305μg/g, range <30-1586μg/g; p=0.049), including 4 patients achieving undetectable levels at end of treatment. A decrease in endoscopic Mayo score and histologic Riley index confirmed the beneficial effect. However, an increase of calprotectin levels and disease activity was observed after cessation of bilberry intake. No serious adverse events were observed. CONCLUSIONS: This is the first report on the promising therapeutic potential of a standardized anthocyanin-rich bilberry preparation in UC in humans. These results clearly indicate a therapeutic potential of bilberries in UC. Further studies on mechanisms and randomized clinical trials are warranted.

Statistics

Citations

24 citations in Web of Science®
30 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

1 download since deposited on 29 Dec 2012
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Institute of Pathology and Molecular Pathology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
04 Faculty of Medicine > University Hospital Zurich > Clinic for Gastroenterology and Hepatology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2013
Deposited On:29 Dec 2012 11:59
Last Modified:05 Apr 2016 16:15
Publisher:Elsevier
ISSN:1873-9946
Publisher DOI:https://doi.org/10.1016/j.crohns.2012.07.010
PubMed ID:22883440

Download

Preview Icon on Download
Filetype: PDF - Registered users only
Size: 746kB
View at publisher